The occurrence of neointimal hyperplasia after flow-diverter implantation is associated with cardiovascular risks factors and the stent design.


Journal

Journal of neurointerventional surgery
ISSN: 1759-8486
Titre abrégé: J Neurointerv Surg
Pays: England
ID NLM: 101517079

Informations de publication

Date de publication:
Jun 2019
Historique:
received: 19 09 2018
revised: 10 10 2018
accepted: 12 10 2018
pubmed: 12 11 2018
medline: 31 7 2019
entrez: 12 11 2018
Statut: ppublish

Résumé

Neo-intimal hyperplasia (NIH) is frequently observed after flow-diverter stent (FDS) implantation. Although mostly asymptomatic, this vascular response can sometimes lead to delayed ischemic strokes. This study intended to evaluate the factors potentially influencing the rates of NIH following FDS treatment. All aneurysm treatments performed with a Pipeline embolization device (PED) or a SILK stent from May 2011 to May 2015 were collected in a prospectively maintained database. Patient demographics, clinical, and angiographic outcomes including both digital subtraction angiography and C-arm cone-beam CT were registered. Two blind reviewers rated the presence of NIH on a binary scale (present/absent). From 148 patients, 63 datasets were available for analysis. Inter-reader agreement was excellent (Kappa=0.88). NIH was positively correlated with smoking, dyslipidemia, and high blood pressure, but not with aneurysm characteristics. At early follow-up (<12 months), NIH was more frequently associated with the use of the SILK stent (68%) rather than the PED (38%): P<0.02. At long-term follow-up, the NIH rate in the total population dropped from 55% to 26% with no more significant difference between the two stents. The complete occlusion rate as seen in early follow-up was higher in the SILK group with 76% vs 65% but without statistical significance (P=0.4). NIH is a dual-vessel reaction after FDS implant. When planning a treatment in locations at risk of ischemic complications if severe NIH would occur, then the stent design should be considered. However, minimal NIH might also be needed as it is involved in aneurysm healing. Before treatment patients should be recommended best medical management of their cardiovascular risks factors to prevent an excessive NIH reaction.

Sections du résumé

BACKGROUND BACKGROUND
Neo-intimal hyperplasia (NIH) is frequently observed after flow-diverter stent (FDS) implantation. Although mostly asymptomatic, this vascular response can sometimes lead to delayed ischemic strokes. This study intended to evaluate the factors potentially influencing the rates of NIH following FDS treatment.
MATERIAL AND METHODS METHODS
All aneurysm treatments performed with a Pipeline embolization device (PED) or a SILK stent from May 2011 to May 2015 were collected in a prospectively maintained database. Patient demographics, clinical, and angiographic outcomes including both digital subtraction angiography and C-arm cone-beam CT were registered. Two blind reviewers rated the presence of NIH on a binary scale (present/absent).
RESULTS RESULTS
From 148 patients, 63 datasets were available for analysis. Inter-reader agreement was excellent (Kappa=0.88). NIH was positively correlated with smoking, dyslipidemia, and high blood pressure, but not with aneurysm characteristics. At early follow-up (<12 months), NIH was more frequently associated with the use of the SILK stent (68%) rather than the PED (38%): P<0.02. At long-term follow-up, the NIH rate in the total population dropped from 55% to 26% with no more significant difference between the two stents. The complete occlusion rate as seen in early follow-up was higher in the SILK group with 76% vs 65% but without statistical significance (P=0.4).
CONCLUSION CONCLUSIONS
NIH is a dual-vessel reaction after FDS implant. When planning a treatment in locations at risk of ischemic complications if severe NIH would occur, then the stent design should be considered. However, minimal NIH might also be needed as it is involved in aneurysm healing. Before treatment patients should be recommended best medical management of their cardiovascular risks factors to prevent an excessive NIH reaction.

Identifiants

pubmed: 30415222
pii: neurintsurg-2018-014441
doi: 10.1136/neurintsurg-2018-014441
doi:

Types de publication

Journal Article

Langues

eng

Pagination

610-613

Informations de copyright

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: JC: Educational scholarships from Medtronic Neurovascular and Microvention/Terumo. JM: consultant for Medtronic, Microvention, Stryker, and Balt. LS: consultant for Stryker, MicroVention, Medtronic, Balt.

Auteurs

Jildaz Caroff (J)

Department of Interventional Neuroradiology, NEURI Centre, Bicêtre Hospital, Le Kremlin-Bicêtre, France.

Marta Iacobucci (M)

Department of Interventional Neuroradiology, NEURI Centre, Bicêtre Hospital, Le Kremlin-Bicêtre, France.

Aymeric Rouchaud (A)

Department of Radiology, Limoges University Hospital, Limoges, France.
CNRS, XLIM, UMR 7252, University of Limoges, Limoges, France.

Cristian Mihalea (C)

Department of Interventional Neuroradiology, NEURI Centre, Bicêtre Hospital, Le Kremlin-Bicêtre, France.

Fernando Mota de Carvalho (FM)

Department of Radiology, Neuroradiology Section, Hospital Antonio Prudente, Fortaleza, Brazil.

Victor Erwin D Jocson (VED)

The Medical City, Makati Medical Centre, Asian Hospital and Medical Centre, Manila, Philippines.

Vanessa Chalumeau (V)

Department of Interventional Neuroradiology, NEURI Centre, Bicêtre Hospital, Le Kremlin-Bicêtre, France.

Valerio Da Ros (V)

Dipartimento di Diagnostica per Immagini e Radiologia Interventistica, Policlinico Universitario di Roma 'Tor Vergata', Rome, Italy.

Robert M King (RM)

New England Center for Stroke Research, Department of Radiology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.

Rose Arslanian (R)

New England Center for Stroke Research, Department of Radiology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.

Léon Ikka (L)

Department of Interventional Neuroradiology, NEURI Centre, Bicêtre Hospital, Le Kremlin-Bicêtre, France.

Nidhal Ben Achour (N)

Department of Interventional Neuroradiology, NEURI Centre, Bicêtre Hospital, Le Kremlin-Bicêtre, France.

Jacques Moret (J)

Department of Interventional Neuroradiology, NEURI Centre, Bicêtre Hospital, Le Kremlin-Bicêtre, France.

Laurent Spelle (L)

Department of Interventional Neuroradiology, NEURI Centre, Bicêtre Hospital, Le Kremlin-Bicêtre, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH